HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Tiezzi, Daniel G ^a   Andrade, Jurandyr M ^a   Ribeiro Silva, Alfredo ^a   Zola, Fábio E ^a   Marana, Heitor R C ^a   Tiezzi, Marcelo G ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b S/A   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P21; PROTEIN P53; TAMOXIFEN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; ASTHENIA; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; FEBRILE NEUTROPENIA; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MASTECTOMY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHENOTYPE; PREOPERATIVE CARE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; TAXOIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33947207819     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-36     Document Type: Article

References (31)

1. Beriwal S Schwartz GF Komarnicky L Garcia-Young JA Breast-conserving therapy after neoadjuvant chemotherapy: Long-term results Breast J 2006 12 2 159-164 10.1111/j.1075-122X.2006.00225.x 16509842
2. Fisher B Brown A Mamounas E Wieand S Robidoux A Margolese RG Cruz AB Jr. Fisher ER Wickerham DL Wolmark N DeCillis A Hoehn JL Lees AW Dimitrov NV Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 1997 15 7 2483-2493 9215816
3. Fisher B Bryant J Wolmark N Mamounas E Brown A Fisher ER Wickerham DL Begovic M DeCillis A Robidoux A Margolese RG Cruz AB Jr. Hoehn JL Lees AW Dimitrov NV Bear HD Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 1998 16 8 2672-2685 9704717
4. Amat S Abrial C Penault-Llorca F Delva R Bougnoux P Leduc B Mouret-Reynier MA Mery-Mignard D Bleuse JP Dauplat J Cure H Chollet P High prognostic significance of residual disease after neoadjuvant chemotherapy: A retrospective study in 710 patients with operable breast cancer Breast Cancer Res Treat 2005 94 3 255-263 10.1007/ s10549-005-9008-8 16267618
5. Bonadonna G Veronesi U Brambilla C Ferrari L Luini A Greco M Bartoli C Coopmans de Yoldi G Zucali R Rilke F Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more J Natl Cancer Inst 1990 82 19 1539-1545 10.1093/jnci/82.19.1539 2402015
6. Schwartz GF Meltzer AJ Lucarelli EA Cantor JP Curcillo PG 2nd Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast J Am Coll Surg 2005 201 3 327-334 10.1016/ j.jamcollsurg.2005.03.015 16125064
7. Tiezzi DG De Andrade JM Candido dos Reis FJ Marana HR Ribeiro-Silva A Tiezzi MG Pereira AP Apoptosis induced by neoadjuvant chemotherapy in breast cancer Pathology 2006 38 1 21-27 10.1080/00313020500465315 16484003
8. Hennessy BT Gonzalez-Angulo AM Hortobagyi GN Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics Nat Clin Pract Oncol 2005 2 12 598-599 10.1038/ ncponc0375 16341096
9. Morse DL Gray H Payne CM Gillies RJ Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells Mol Cancer Ther 2005 4 10 1495-1504 10.1158/1535-7163.MCT-05-0130 16227398
10. Sinha BK Politi PM Anthracyclines Cancer Chemother Biol Response Modif 1990 11 45-57 2223402
11. Goble S Bear HD Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: The potential and the questions Surg Clin North Am 2003 83 4 943-971 10.1016/S0039-6109(03)00071-9 12875604
12. Hayward JL Carbone PP Heusen JC Kumaoka S Segaloff A Rubens RD Assessment of response to therapy in advanced breast cancer Br J Cancer 1977 35 3 292-298 856236
13. Allal AS Gervaz P Brundler MA Cyclin D1, cyclin E, and p21 have no apparent prognostic value in anal carcinomas treated by radiotherapy with or without chemotherapy Br J Cancer 2004 91 7 1239-1244 10.1038/ sj.bjc.6602111 15292923
14. Jacobs TW Gown AM Yaziji H Barnes MJ Schnitt SJ Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system J Clin Oncol 1999 17 7 1983-1987 10561248
15. Jacobs TW Gown AM Yaziji H Barnes MJ Schnitt SJ Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer J Clin Oncol 1999 17 7 1974-1982 10561247
16. Ramaswamy B Povoski SP Rhoades C Allen J Hauger M Young D Burak W Farrar W Yee L Kendra K Somasundaram S Orlowski RZ Shapiro CL Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer Breast Cancer Res Treat 2005 93 1 67-74 10.1007/ s10549-005-3784-z 16184461
17. Kaufmann M Hortobagyi GN Goldhirsch A Scholl S Makris A Valagussa P Blohmer JU Eiermann W Jackesz R Jonat W Lebeau A Loibl S Miller W Seeber S Semiglazov V Smith R Souchon R Stearns V Untch M von Minckwitz G Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update J Clin Oncol 2006 24 12 1940-1949 10.1200/JCO.2005.02.6187 16622270
18. Han S Kim SB Kang SS Noh WC Paik NS Chang ES Kim JR Lim SH Park HS A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer Breast Cancer Res Treat 2006 98 1 57-61 10.1007/s10549-005-9131-6 16752226
19. Ganem G Tubiana-Hulin M Fumoleau P Combe M Misset JL Vannetzel JM Bachelot T De Ybarlucea LR Lotz V Bendahmane B Dieras V Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer Ann Oncol 2003 14 11 1623-1628 10.1093/annonc/mdg449 14581269
20. Bottini A Berruti A Bersiga A Brunelli A Brizzi MP Marco BD Cirillo F Bolsi G Bertoli G Alquati P Dogliotti L Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours Anticancer Res 1996 16 5B 3105-3110 8920776
21. Bottini A Berruti A Bersiga A Brizzi MP Brunelli A Gorzegno G DiMarco B Aguggini S Bolsi G Cirillo F Filippini L Betri E Bertoli G Alquati P Dogliotti L p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients Clin Cancer Res 2000 6 7 2751-2758 10914720
22. Stearns V Singh B Tsangaris T Crawford JG Novielli A Ellis MJ Isaacs C Pennanen M Tibery C Farhad A Slack R Hayes DF A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer Clin Cancer Res 2003 9 1 124-133 12538460
23. Taucher S Rudas M Mader RM Gnant M Sporn E Dubsky P Roka S Bachleitner T Fitzal F Kandioler D Wenzel C Steger GG Mittlbock M Jakesz R Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer Breast Cancer Res Treat 2003 82 3 207-213 10.1023/B:BREA.0000004378.15859.51 14703068
24. Zhang F Yang Y Smith T Kau SW McConathy JM Esteva FJ Kuerer HM Symmans WF Buzdar AU Hortobagyi GN Pusztai L Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma Cancer 2003 97 7 1758-1765 10.1002/cncr.11245 12655533
25. Fernandez-Sanchez M Gamboa-Dominguez A Uribe N Garcia-Ulloa AC Flores-Estrada D Candelaria M Arrieta O Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer Med Oncol 2006 23 2 171-183 10.1385/ MO:23:2:171 16720917
26. Learn PA Yeh IT McNutt M Chisholm GB Pollock BH Rousseau DL Jr. Sharkey FE Cruz AB Kahlenberg MS HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma Cancer 2005 103 11 2252-2260 10.1002/cncr.21037 15834928
27. Ravdin PM Siminoff LA Davis GJ Mercer MB Hewlett J Gerson N Parker HL Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer J Clin Oncol 2001 19 4 980-991 11181660
28. Ahluwalia MS Daw HA Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer J Clin Oncol 2005 23 30 7759-60; author reply 7760-1 10.1200/JCO.2005.03.0213 16234551
29. Montemurro F Aglietta M Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer Clin Breast Cancer 2005 6 1 77-80 15899075
30. Ayers M Symmans WF Stec J Damokosh AI Clark E Hess K Lecocke M Metivier J Booser D Ibrahim N Valero V Royce M Arun B Whitman G Ross J Sneige N Hortobagyi GN Pusztai L Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J Clin Oncol 2004 22 12 2284-2293 10.1200/JCO.2004.05.166 15136595
31. Thuerigen O Schneeweiss A Toedt G Warnat P Hahn M Kramer H Brors B Rudlowski C Benner A Schuetz F Tews B Eils R Sinn HP Sohn C Lichter P Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer J Clin Oncol 2006 24 12 1839-1845 10.1200/JCO.2005.04.7019 16622258